LogixX Pharma is managed by pharmaceutical entrepeneurs with experience in developing and commercialising therapeutic options for patients needs.
With experience spanning commercialisation of research and development projects, they deploy their expertise in late-phase clinical trials, registration and approval processes, and in market access activities across different markets.
Michael Close, CEO and founder
Since founding the Company and becoming CEO in 2010, Michael has focused on leveraging the uniqueness of LogixX Pharma in serving its clients with an emphasis on strong execution and the highest ethical and regulatory standards primarily in the metabolic and paediatric markets. Today LogixX Pharma generates a significant proportion of it’s growth in male and female fertility and sexual health products.
Overseeing the development of licensing and partnerships, the identification and initiation of new projects, and the business unit’s entire portfolio, Michael has a vision to support patient communities, health care professionals and employees in growing the company’s portfolio through innovation, lifecycle management and geographical expansion. He has a strong track record in commercialising novel therapeutics to market by developing successful partnerships, applying expertise in commercial and regulatory activities, registration and approval, and advancing market access.
Since 2010, Michael has led the company’s activities in partnering with other companies without a presence in the UK market. He partnered several Italian, German and US based start-up companies in providing a Commercial and Regulatory foundation in which to grow. He supported Pharmaceutical product transfers back to the originating company to further commercialise the assets at Group level in the areas of oncology and rare/orphan diseases. He partnered with Alfasigma to support the UK health science business in October 2013.
Michael has extensive experience in commercialisation, logistics and development of medicines and medical devices in several therapeutic areas. Michael Close is also the MHRA approved Responsible Person of LogixX Pharma Ltd, and also serves on the board of Shard Speciality Pharma Ltd. Prior to LogixX Pharma, Michael held a number of senior posts with Merck Serono Ltd, and previously with Solvay and Bayer. He holds an honours degree in Biomedical Science from the University of Wolverhampton.
Professor Ralf Henkel B.Ed., Ph.D., Habil., Chief ScientiFIC Advisor
Professor Ralf Henkel joined LogixX Pharma as Chief Scientific Advisor in July 2020 following an estimeed career in academic science.
Professor Henkel studied Biology and Chemistry in Marburg, Germany. From January 2014 to May 2020, he was Head of Department of Medical Bioscience at the University of the Western Cape, Bellville, South Africa, where he is now an Extraordinary Professor.
Professor Henkel is also a Visiting Reader in the Department of Metabolism, Digestion and Reproduction at Imperial College London, UK, Honorary Professor at Universidad Peruana Cayetano Heredia, Lima, Peru, and Adjunct Senior Scientist at the American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH.
Professor Henkel is also Editor-in-Chief of ANDROLOGIA. Thus far, a total of 71 students graduated under his supervision. He published 167 research papers and review articles, 47 book chapters as well as 2 books; his h-index is 41.
Chief Scientific Advisor: LogixX Pharma, Reading, UK
Visiting Reader: Department of Metabolism, Digestion and Reproduction, Imperial College London, UK
Extraordinary Professor: University of the Western Cape, Bellville, South Africa
Honorary Professor: Universidad Peruana Cayetano Heredia, Lima, Peru
Adjunct Senior Scientist: American Center for Reproductive Medicine, Department of Urology, Cleveland Clinic, Cleveland, OHIO.
Editor-in-Chief: Andrologia
Associate Editor: Reproductive Sciences
Section Editor: Reproductive Biology and Endocrinology
HOME